<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): March 2, 2000
CuraGen Corporation
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-23223 06-1331400
- --------------------------------------------------------------------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (203) 401-3330
Page 1 of 5 pages
<PAGE>
ITEM 5. OTHER EVENTS.
On March 2, 2000, CuraGen Corporation announced that its Board of Directors
had approved a two-for-one split of the Company's common stock payable to
stockholders in the form of a stock dividend. On Thursday, March 30, 2000,
stockholders of record will receive one additional share of CuraGen's common
stock for every share each shareholder owns at the close of business on March
15, 2000. CuraGen common stock will begin trading on a split-adjusted basis on
Friday, March 31, 2000. The information contained in such press release is
incorporated herein by reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
99.1 The Registrant's Press Release dated March 2, 2000.
Page 2 of 5 pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CURAGEN CORPORATION
(Registrant)
Date: March 3, 2000 By: /s/ David M. Wurzer
---------------------------------------
David M. Wurzer
Executive Vice President, Treasurer and
Chief Financial Officer
Page 3 of 5 pages
<PAGE>
EXHIBIT INDEX
-------------
Exhibit Sequential
Number Description Page Number
- ------- ----------- -----------
99.1 The Registrant's Press Release 5
dated March 2, 2000.
Page 4 of 5 pages
<PAGE>
Exhibit 99.1
Press Release of the Registrant
CURAGEN'S BOARD OF DIRECTORS AUTHORIZES TWO-FOR-ONE STOCK SPLIT
NEW HAVEN, CONNECTICUT - MARCH 2, 2000 - CuraGen Corporation (NASDAQ: CRGN), an
------------
integrated genomics based drug discovery and development company, today
announced that its Board of Directors has approved a two-for-one split of the
Company's common stock payable to stockholders in the form of a stock dividend.
On Thursday, March 30, 2000, stockholders of record will receive one additional
share of CuraGen's common stock for every share each shareholder owns at the
close of business on March 15, 2000. CuraGen common stock will begin trading on
a split-adjusted basis on Friday, March 31, 2000.
As of March 1, 2000 CuraGen Corporation had approximately 18.2 million common
shares outstanding. Subsequent to the completion of the stock split, CuraGen
will have approximately 36.4 million shares of common stock outstanding.
CuraGen Corporation is advancing the discovery and development of pharmaceutical
and life science products through the systematic application of genomics.
CuraGen's fully integrated, Internet-based functional genomics technologies,
services, and information systems are designed to rapidly generate comprehensive
information about genes, human genetic variations, gene expression, protein
pathways, and potential products that affect these pathways. The Company is
applying these functional genomics technologies to develop protein drugs,
antibody drugs, and small molecule drug targets. CuraGen's research
collaborators include Abgenix, Biogen, COR Therapeutics, Genentech, Glaxo
Wellcome, Hoffmann-La Roche, Pioneer Hi-Bred International, and Roche Vitamins.
CuraGen employs over 300 people and is headquartered in New Haven, CT.
Additional Company information is available at http://www.curagen.com.
----------------------
This release may contain forward-looking statements that are subject to certain
risks and uncertainties, including the Company's ability to successfully enhance
and develop its technologies. Such statements are based on management's current
expectations and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in the forward-
looking statements. The Company cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a result
of various factors, including, but not limited to, the following: the Company's
early stage of development, technological uncertainty and product development
risks, uncertainty of additional funding, reliance on research collaborations,
competition, the Company's ability to protect its patents and proprietary rights
and uncertainties relating to commercialization rights.
Page 5 of 5 pages
